PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
0.700
-0.053 (-7.03%)
At close: Mar 9, 2026, 4:00 PM EDT
0.741
+0.041 (5.87%)
After-hours: Mar 9, 2026, 5:14 PM EDT

PharmaCyte Biotech Cash Flow Statement

Millions USD. Fiscal year is May - Apr.
Fiscal Year
TTM FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Oct '25 Apr '25 Apr '24 Apr '23 Apr '22 Apr '21 2020 - 2016
Net Income
-7.0730.660.33-4.32-4.24-3.55
Upgrade
Asset Writedown & Restructuring Costs
--2---
Upgrade
Loss (Gain) From Sale of Investments
-6.6-26.531.57---
Upgrade
Stock-Based Compensation
0.260.480.670.650.110.44
Upgrade
Other Operating Activities
8.04-8.94-7.030.17--0.08
Upgrade
Change in Accounts Payable
0.590.010.26-0.240.03-0.01
Upgrade
Change in Other Net Operating Assets
0.271.350.04-0.05-0.02-0.13
Upgrade
Operating Cash Flow
-4.52-2.98-2.15-3.79-4.12-3.33
Upgrade
Investment in Securities
-3-7----
Upgrade
Other Investing Activities
---5---
Upgrade
Investing Cash Flow
-3-7-5---
Upgrade
Long-Term Debt Repaid
-----0.05-0.06
Upgrade
Total Debt Repaid
-----0.05-0.06
Upgrade
Net Debt Issued (Repaid)
-----0.05-0.06
Upgrade
Issuance of Common Stock
--0087.364.7
Upgrade
Repurchase of Common Stock
-0.4-2.54-28.2-13.56--
Upgrade
Financing Cash Flow
2.09-25.03-10.71-13.5687.314.64
Upgrade
Foreign Exchange Rate Adjustments
-0-0-0-0.0100
Upgrade
Net Cash Flow
-5.43-35.01-17.86-17.3683.21.31
Upgrade
Cash Interest Paid
----00
Upgrade
Cash Income Tax Paid
--0-00
Upgrade
Levered Free Cash Flow
-7.51-13.343.28-3.52-2.62-1.97
Upgrade
Unlevered Free Cash Flow
-7.51-13.343.28-3.52-2.62-1.97
Upgrade
Change in Working Capital
0.851.360.3-0.30.01-0.15
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.